For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a cure. Yet in many cases, even when patients receive the exact same medication, the treatment unexpectedly fails.
In diffuse large B-cell lymphoma (DLBCL)—the most common and fast-growing form of non-Hodgkin lymphoma—the standard frontline therapy is rituximab. The drug works by targeting and binding to the CD20 protein on the surface of cancerous B-cells, signaling the patient's immune system to destroy them. However, between 40% and 50% of patients develop resistance to the treatment. While medical consensus previously held that resistance was primarily driven by cancer cells losing their surface CD20 markers, that theory failed to explain every case.
Now, a research team at Samsung Medical Center led by Professor Kim Seok-jin of the Division of Hematology-Oncology has uncovered a key driver of drug resistance: the cancer cells release microscopic "decoys" directly into the bloodstream to intercept the drug before it ever reaches the tumor.
Microscopic decoys that intercept target drugs
The culprits are CD20-positive extracellular vesicles—nanometer-sized particles shed by tumor cells into the circulating blood. Because these vesicles carry the same CD20 markers on their surface as the primary cancer cells, rituximab cannot distinguish between them and real tumor targets.
Extracellular vesicles are naturally produced by healthy cells to exchange biological signals. However, when researchers observed cellular dynamics in real time using 4D optical microscopy, they confirmed that these tumor-derived vesicles act as "antigen decoys." Rituximab preferentially bound to the circulating vesicles first, drastically reducing the volume of antibodies available to attack actual cancer cells.
In cellular experiments, the vesicles caused further damage beyond mere interference. They actively promoted lymphoma cell proliferation while suppressing both the therapeutic effect of rituximab and the natural tumor-killing capability of immune cells—effectively creating a protective environment for the cancer to thrive.
Predicting treatment response through a simple blood draw
To evaluate the clinical impact, the research team analyzed serum vesicle levels in an initial group of 26 newly diagnosed DLBCL patients, followed by a validation cohort of 90 patients. The findings were consistent: patients with higher pre-treatment vesicle levels demonstrated significantly lower survival rates. Crucially, this correlation held true even after adjusting for the International Prognostic Index (IPI), an established clinical tool used to assess disease progression.
While elevated vesicle levels do not guarantee treatment failure, they strongly correlate with reduced drug efficacy and a poorer prognosis.
Although the study represents an early-stage discovery conducted within a single medical institution, it establishes a compelling foundation for precision oncology. By measuring extracellular vesicle levels through a routine blood test prior to starting therapy, oncologists may soon be able to identify high-risk patients early and tailor alternative treatment strategies from the outset.
The findings were published in the international medical journal Blood Cancer Journal. The study's co-authors include doctoral candidate Park Bon (first author) and researcher Yoo Kyung-joo of the Samsung Advanced Institute for Health Sciences & Technology; researcher Choi Min-kyu of the Seoul National University Institute of Medical Science; and Professors Yoon Sang-eun, Kim Won-seok, and Kim Seok-jin of Samsung Medical Center (corresponding authors).
